Pulmonary complications of pneumococcal community-acquired pneumonia: incidence, predictors, and outcomes

Clinical Microbiology and Infection

Volumn 18, Issue 11, 2012, Pages 1134-1142

  Cilloniz C ^a,b,c   Ewig, S ^d   Polverino, E ^a,b,c   Munoz Almagro C ^e   Marco, F ^a   Gabarrus A ^a,b,c   Menendez R ^c,f   Mensa, J ^a   Torres, A ^a,b,c  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d Augusta Kranken Anstalt   (Germany)

^e University Hospital Sant Joan de Déu Esplugues   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Complicated pneumonia; Pneumococcus; Pneumonia; Pulmonary complications; Serotypes

Indexed keywords

AMIKACIN; AMIKACIN PLUS LEVOFLOXACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; C REACTIVE PROTEIN; CEFOTAXIME; CEFTRIAXONE; CEFTRIAXONE PLUS CLINDAMYCIN; CLAVULANIC ACID; CLINDAMYCIN; CREATININE; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; MEROPENEM; MEROPENEM PLUS LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; CHRONIC LIVER DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; EMPYEMA; FEMALE; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INFECTION COMPLICATION; INTENSIVE CARE UNIT; LENGTH OF STAY; LUNG COMPLICATION; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PENICILLIN RESISTANCE; PLEURA EFFUSION; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SEROTYPE; SHOCK; SPAIN; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

STREPTOCOCCUS PNEUMONIAE;

EID: 84867711648     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03692.x     Document Type: Article

References (30)

1. Van Der PT, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009; 374: 1543-1556.
2. Goldbart AD, Leibovitz E, Porat N et al. Complicated community acquired pneumonia in children prior to the introduction of the pneumococcal conjugated vaccine. Scand J Infect Dis 2009; 41: 182-187.
3. Munoz-Almagro C, Jordan I, Gene A et al. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008; 46: 174-182.
4. Ardanuy C, Tubau F, Pallares R et al. Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007. Clin Infect Dis 2009; 48: 57-64.
5. Light RW, Girard WM, Jenkinson SG et al. Parapneumonic effusions. Am J Med 1980; 69: 507-512.
6. Taryle DA, Potts DE, Sahn SA. The incidence and clinical correlates of parapneumonic effusions in pneumococcal pneumonia. Chest 1978; 74: 170-173.
7. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (suppl 2): S27-S72.
8. Menendez R, Torres A, Zalacain R et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004; 59: 960-965.
9. Lim WS, Baudouin SV, George RC et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 (suppl 3): iii1-iii55.
10. Roson B, Carratala J, Fernandez-Sabe N et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004; 164: 502-508.
11. Chalmers JD, Singanayagam A, Murray MP et al. Risk factors for complicated parapneumonic effusion and empyema on presentation to hospital with community-acquired pneumonia. Thorax 2009; 64: 592-597.
12. Garcia-Vidal C, Fernandez-Sabe N, Carratala J et al. Early mortality in patients with community-acquired pneumonia: causes and risk factors. Eur Respir J 2008; 32: 733-739.
13. Obando I, Munoz-Almagro C, Arroyo LA et al. Pediatric parapneumonic empyema, Spain. Emerg Infect Dis 2008; 14: 1390-1397.
14. Tan TQ, Mason EO Jr, Barson WJ et al. Clinical characteristics and outcome of children with pneumonia attributable to penicillin-susceptible and penicillin-nonsusceptible Streptococcus pneumoniae. Pediatrics 1998; 102: 1369-1375.
15. Byington CL, Hulten KG, Ampofo K et al. Molecular epidemiology of pediatric pneumococcal empyema from 2001 to 2007 in Utah. J Clin Microbiol 2010; 48: 520-525.
16. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: eighteenth informational supplement. CLSI document M100-S18. Wayne, PA: CLSI, 2008.
17. Hosmer D, Lemeshow S. Applied logistic regression. New York: Wiley, 1989.
18. Ahmed RA, Marrie TJ, Huang JQ. Thoracic empyema in patients with community-acquired pneumonia. Am J Med 2006; 119: 877-883.
19. Saldias PF, Viviani GP, Pulgar BD et al. Prognostic factors and mortality in immunocompetent adult patients hospitalized with community-acquired pneumococcal pneumonia. Rev Med Chil 2009; 137: 1545-1552.
20. Wexler ID, Knoll S, Picard E et al. Clinical characteristics and outcome of complicated pneumococcal pneumonia in a pediatric population. Pediatr Pulmonol 2006; 41: 726-734.
21. Liapikou A, Ferrer M, Polverino E et al. Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society Guidelines to predict an intensive care unit admission. Clin Infect Dis 2009; 48: 377-385.
22. Garcia-Vidal C, Ardanuy C, Tubau F et al. Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes. Thorax 2010; 65: 77-81.
23. Chibuk TK, Robinson JL, Hartfield DS. Pediatric complicated pneumonia and pneumococcal serotype replacement: trends in hospitalized children pre and post introduction of routine vaccination with Pneumococcal Conjugate Vaccine (PCV7). Eur J Pediatr 2010; 169: 1123-1128.
24. Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine 2010; 28: 4249-4259.
25. de Roux A, Cavalcanti M, Marcos MA et al. Impact of alcohol abuse in the etiology and severity of community-acquired pneumonia. Chest 2006; 129: 1219-1225.
26. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008; 121: 219-225.
27. Lim WS, van der Eerden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377-382.
28. Gutierrez P, Closa D, Piner R et al. Macrophage activation in exacerbated chronic obstructive pulmonary disease with and without community-acquired pneumonia. Eur Respir J 2010; 36: 285-291.
29. Strassburg A, Luers A, Dalhoff K. Decreased apoptosis of pulmonary PMN in COPD patients with community-acquired pneumonia. Clin Respir J 2010; 4: 111-119.
30. Menendez R, Torres A, Zalacain R et al. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am J Respir Crit Care Med 2005; 172: 757-762.